Curium Delivers First PYLCLARI® (18F-DCFPyL) Doses To Prostate Cancer Patients In Poland, Expanding European Access

Curium, a global leader in nuclear medicine, has announced that patients in Poland have now received the first doses of PYLCLARI® (piflufolastat 18F), also known as 18F-DCFPyL. This marks an important step in expanding access to advanced diagnostic tools for prostate cancer across Europe. PYLCLARI is a diagnostic radiopharmaceutical used in adult patients with prostate cancer. It helps detect prostate cancer cells in individuals with high-risk disease before they begin curative treatment. 

It is also used to identify the location of recurrent prostate cancer in patients showing rising PSA (prostate-specific antigen) levels after their initial treatment. By providing highly accurate imaging, PYLCLARI supports doctors in making more informed decisions about treatment planning and disease monitoring. In Poland, the manufacturing and distribution of PYLCLARI are being handled by Curium’s new partner, Synektik Pharma Sp. z o.o., enabling reliable local production and supply.

Ciril Faia, CEO of Curium International, said that the company is very pleased to see PYLCLARI become available to patients in Poland. He noted that as Curium continues to strengthen its role in nuclear medicine, expanded access to PYLCLARI across Europe is giving physicians more diagnostic options to better detect and track prostate cancer, ultimately benefiting patients.

Przemysław Kozanecki, CEO of Synektik Pharma, expressed pride in the partnership with Curium and highlighted the importance of supplying PYLCLARI in Poland. He added that Synektik’s growing PET PSMA product portfolio will significantly contribute to improving prostate cancer management for patients in the country.

Prostate cancer remains the most common cancer among men in Poland, with approximately 23,000 new cases diagnosed each year. The availability of PYLCLARI in Poland is part of Curium’s broader European rollout. The product is already accessible to prostate cancer patients in several countries, including Greece, Italy, France, Spain, Austria, Germany, Belgium, Finland, Sweden, the Czech Republic, Switzerland, the Netherlands, and now Poland.

In the United States, the related product PYLARIFY® (piflufolastat F 18 injection) was approved by the FDA in May 2021. Curium obtained an exclusive license to develop and commercialize PYLCLARI in Europe in 2018, supporting its strategy to expand access to advanced nuclear medicine diagnostics across the region.